Citius Pharmaceuticals Inkomsten in het verleden

Verleden criteriumcontroles 0/6

De winst van Citius Pharmaceuticals is gedaald met een gemiddeld jaarlijks tempo van -19.6%, terwijl de winst van de sector Pharmaceuticals jaarlijks groeide met 1.2%.

Belangrijke informatie

-19.6%

Groei van de winst

31.0%

Groei van de winst per aandeel

Pharmaceuticals Groei van de industrie	6.0%
Inkomstengroei	n/a
Rendement op eigen vermogen	-44.4%
Nettomarge	n/a
Laatste winstupdate	30 Jun 2024

Recente prestatie-updates uit het verleden

Geen updates

Recent updates

We Think Citius Pharmaceuticals (NASDAQ:CTXR) Needs To Drive Business Growth Carefully

Apr 06

We're Keeping An Eye On Citius Pharmaceuticals' (NASDAQ:CTXR) Cash Burn Rate

Dec 08

Will Citius Pharmaceuticals (NASDAQ:CTXR) Spend Its Cash Wisely?

Aug 01

We Think Citius Pharmaceuticals (NASDAQ:CTXR) Can Afford To Drive Business Growth

Apr 12

Here's Why We're Watching Citius Pharmaceuticals' (NASDAQ:CTXR) Cash Burn Situation

Dec 25

Citius Pharma submits biologics license application to FDA for immunotherapy I/ONTAK

Sep 28

Citius Pharmaceuticals GAAP EPS of -$0.06

Aug 11

Here's Why Citius Pharmaceuticals (NASDAQ:CTXR) Must Use Its Cash Wisely

Aug 05

Citius holds pre-biologics license application meeting with FDA for immunotherapy I/ONTAK

Jul 12

We Think Citius Pharmaceuticals (NASDAQ:CTXR) Can Afford To Drive Business Growth

Dec 04

Citius Pharmaceuticals, Inc.: Burning Cash Before Commercialization

Sep 26

Companies Like Citius Pharmaceuticals (NASDAQ:CTXR) Are In A Position To Invest In Growth

Aug 28

Citius: Halt For Superiority On The Horizon

Jun 15

We Think Citius Pharmaceuticals (NASDAQ:CTXR) Can Afford To Drive Business Growth

May 15

Citius Pharmaceuticals shares rise in anticipation of Mino-Lok phase 3 results

Apr 26

Is Citius Pharmaceuticals (NASDAQ:CTXR) In A Good Position To Deliver On Growth Plans?

Dec 18

Opbrengsten en kosten

Hoe Citius Pharmaceuticals geld verdient en uitgeeft. Gebaseerd op laatst gerapporteerde winst, op LTM-basis.

Inkomsten en omzetgeschiedenis

NasdaqCM:CTXR Opbrengsten, kosten en inkomsten (USD Millions )
Datum	Inkomsten	G+A Uitgaven	R&D-uitgaven
30 Jun 24	-40	29	12
31 Mar 24	-37	26	13
31 Dec 23	-39	25	14
30 Sep 23	-34	22	15
30 Jun 23	-31	18	16
31 Mar 23	-31	17	17
31 Dec 22	-28	16	16
30 Sep 22	-34	16	18
30 Jun 22	-31	15	16
31 Mar 22	-29	15	13
31 Dec 21	-26	13	12
30 Sep 21	-25	11	12
30 Jun 21	-24	11	11
31 Mar 21	-21	9	12
31 Dec 20	-21	9	12
30 Sep 20	-18	9	9
30 Jun 20	-17	8	9
31 Mar 20	-17	8	9
31 Dec 19	-16	7	9
30 Sep 19	-16	7	9
30 Jun 19	-15	7	8
31 Mar 19	-12	7	6
31 Dec 18	-13	6	8
30 Sep 18	-13	7	7
30 Jun 18	-13	7	5
31 Mar 18	-13	8	5
31 Dec 17	-11	8	2
30 Sep 17	-10	7	3
30 Jun 17	-10	7	4
31 Mar 17	-11	6	5
31 Dec 16	-9	5	4
30 Sep 16	-8	5	3
30 Jun 16	-7	3	2
31 Mar 16	-4	2	2
31 Dec 15	-3	1	2
30 Sep 15	-3	1	2
30 Jun 15	-3	2	1
31 Mar 15	-2	1	1
31 Dec 14	-2	1	0
30 Sep 14	-1	1	0
30 Jun 14	-1	0	0
31 Mar 14	-1	0	0

Kwaliteitswinsten: CTXR is momenteel verliesgevend.

Groeiende winstmarge: CTXR is momenteel verliesgevend.

Analyse vrije kasstroom versus winst

Analyse van de winstgroei in het verleden

Winsttrend: CTXR is verliesgevend en de verliezen zijn de afgelopen 5 jaar toegenomen met een snelheid van 19.6% per jaar.

Versnelling van de groei: Het is niet mogelijk om de winstgroei van CTXR over het afgelopen jaar te vergelijken met het gemiddelde over de afgelopen vijf jaar, omdat het bedrijf momenteel verliesgevend is.

Winst versus industrie: CTXR is verlieslatend, waardoor het lastig is om de winstgroei van het afgelopen jaar te vergelijken met die van de Pharmaceuticals industrie ( 54.6% ).

Rendement op eigen vermogen

Hoge ROE: CTXR heeft een negatief Return on Equity ( -44.38% ), omdat het momenteel verliesgevend is.

Citius Pharmaceuticals Inkomsten in het verleden

Verleden criteriumcontroles 0/6

Belangrijke informatie

Recente prestatie-updates uit het verleden

Recent updates

Citius Pharmaceuticals, Inc. has completed a Follow-on Equity Offering in the amount of $3 million.

Forecast breakeven date pushed back to 2026

New major risk - Share price stability

Nasdaq Hearings Panel Grants Citius Pharmaceuticals' Request to Continue its Listing on The Nasdaq Capital Market to Regain Compliance with the Bid Price Rule on or before December 3, 2024

Citius Pharmaceuticals, Inc. and Citius Oncology, Inc. Announce Promising Preliminary Results of an Investigator-Initiated Phase I Clinical Trial of Pembrolizumab (Keytruda®) and Lymphir™ in Cancer Patients with Recurrent Solid Tumors

Citius Pharmaceuticals, Inc. Provides Non-Compliance Update

New minor risk - Market cap size

Citius Pharmaceuticals, Inc. has filed a Follow-on Equity Offering in the amount of $50 million.

Citius Pharmaceuticals, Inc. Receives FDA Approval for LYMPHIR Immunotherapy for the Treatment of Adults with Relapsed or Refractory Cutaneous T-Cell Lymphoma

Price target increased by 22% to US$4.67

Forecast breakeven date pushed back to 2026

Citius Pharmaceuticals, Inc. Achieves Primary and Secondary Endpoints in Phase 3 Trial of Mino-Lok Antibiotic Lock Solution

Citius Pharmaceuticals, Inc. has completed a Follow-on Equity Offering in the amount of $15.000002 million.

Citius Pharmaceuticals, Inc. Announces Addition of City of Hope to UMN's Phase 1 Trial of LYMPHIR in Combination with CAR-T for the Treatment of B-Cell Lymphoma

We Think Citius Pharmaceuticals (NASDAQ:CTXR) Needs To Drive Business Growth Carefully

New minor risk - Share price stability

The Nasdaq Stock Market LLC Grants Citius Pharmaceuticals' Request for an Extension through September 9, 2024 to Evidence Compliance with the Bid Price Rule Pursuant to Nasdaq Listing Rule 5550(a)(2)

Forecast breakeven date pushed back to 2026

Citius Pharmaceuticals, Inc. Announces the Resubmission of the Biologics License Application to the U.S. Food and Drug Administration for Lymphir

New minor risk - Market cap size

Citius Pharmaceuticals, Inc., Annual General Meeting, Mar 12, 2024

Citius Pharmaceuticals, Inc. Completes Enrollment in Pivotal Phase 3 Trial of its Mino-Lok Therapeutic to Salvage Catheters

New major risk - Financial position

New minor risk - Profitability

We're Keeping An Eye On Citius Pharmaceuticals' (NASDAQ:CTXR) Cash Burn Rate

Citius Pharmaceuticals, Inc. Announces Publication in Frontiers of Immunology of Positive Results from Solid Tumor Study of LYMPHIR™ in Combination with Checkpoint Inhibitor

New minor risk - Share price stability

Citius Pharmaceuticals, Inc. Announces Changes to its Audit Committee

Citius Pharmaceuticals Receives Non-Compliance Notice from Nasdaq Stock Market

Citius Pharmaceuticals, Inc. Receives Regulatory Guidance from the U.S. Food and Drug Administration Regarding the Planned Resubmission of the BLA for LYMPHIR

Citius Pharmaceuticals, Inc. Reaches 92 Event Milestone in Mino-Lok Phase 3 Trial

Price target decreased by 21% to US$3.17

Will Citius Pharmaceuticals (NASDAQ:CTXR) Spend Its Cash Wisely?

Citius Pharmaceuticals, Inc. Receives a Complete Response Letter from the U.S. Food and Drug Administration (FDA) for LYMPHIR™ (Denileukin Diftitox) for the Treatment of Patients with Relapsed or Refractory Cutaneous T-Cell Lymphoma

Citius Pharmaceuticals, Inc. Announces Positive Results from the Phase 2b Study of Halo-Lido (CITI-002) for the Treatment of Hemorrhoids

Consensus EPS estimates fall by 24%

We Think Citius Pharmaceuticals (NASDAQ:CTXR) Can Afford To Drive Business Growth

Forecast breakeven date pushed back to 2025

Price target increased by 25% to US$5.00

Forecast breakeven date pushed back to 2025

Citius Pharmaceuticals, Inc. Appoints Dennis M. McGrath to Board of Directors

Here's Why We're Watching Citius Pharmaceuticals' (NASDAQ:CTXR) Cash Burn Situation

Citius Pharmaceuticals, Inc., Annual General Meeting, Feb 07, 2023

Citius Pharmaceuticals, Inc. Announces U.S. Food and Drug Administration Acceptance of Biologics License Application of Denileukin Diftitox for Treatment of Patients with Persistent or Recurrent Cutaneous T-Cell Lymphoma

Price target decreased to US$3.60

Insufficient new directors

Citius Pharmaceuticals, Inc. Submits Biologics License Application to the U.S. Food and Drug Administration for Denileukin Diftitox for the Treatment of Patients with Persistent or Recurrent Cutaneous T-Cell Lymphoma

Citius Pharma submits biologics license application to FDA for immunotherapy I/ONTAK

Citius Pharmaceuticals GAAP EPS of -$0.06

Here's Why Citius Pharmaceuticals (NASDAQ:CTXR) Must Use Its Cash Wisely

Citius Pharmaceuticals, Inc. Holds Pre-BLA Meeting with the FDA for I/ONTAK for the Treatment of Cutaneous T-Cell Lymphoma

Citius holds pre-biologics license application meeting with FDA for immunotherapy I/ONTAK

Citius Pharmaceuticals: Hoping For A Turnaround Strategy

Price target increased to US$4.00

Insufficient new directors

Citius Pharmaceuticals, Inc. Enrolls First Patient in Phase 2B Study of Halo-Lido for the Prescription Treatment of Hemorrhoids

Citius Pharmaceuticals, Inc. Announces Executive Changes

Critical Care Biopharma - Citius Pharmaceuticals

Forecast breakeven date pushed back to 2024

Citius Pharmaceuticals Reports Topline Data from the Pivotal Phase 3 Study of Cancer Immunotherapy I/Ontak (E7777)

Citius: 2022 Is A Year Of Catalysts

Citius Pharmaceuticals Announces FDA Acceptance of IND Application for its Phase 2b Study of Halo-Lido for the Prescription Treatment of Hemorrhoids

Forecast breakeven date moved forward to 2023

Citius Pharmaceuticals, Inc. Completes Enrollment in the Pivotal Phase 3 Study of its Cancer Immunotherapy I/ONTAK for the Treatment of Cutaneous T-Cell Lymphoma

We Think Citius Pharmaceuticals (NASDAQ:CTXR) Can Afford To Drive Business Growth

Citius Pharmaceuticals, Inc.: Burning Cash Before Commercialization

Citius Pharmaceuticals Acquires Dr. Reddy's Laboratories' License for Late-Phase 3 Oncology Immunotherapy (E7777) for the Treatment of Cutaneous T-Cell Lymphoma and other Cancer Indications

Citius Pharmaceuticals, Inc. (NasdaqCM:CTXR) agreed to acquire Rights and Certain Related Assets of Dr. Reddy's Laboratories Limited (BSE:500124) for approximately $150 million.

Companies Like Citius Pharmaceuticals (NASDAQ:CTXR) Are In A Position To Invest In Growth

Citius Pharmaceuticals, Inc. Announces Positive Recommendation by Independent Data Monitoring Committee to Continue the Mino-Lok® Phase 3 Trial as Planned

Citius: Halt For Superiority On The Horizon

Citius Pharmaceuticals Achieves Next Interim Analysis Milestone in its Mino-Lok® Phase 3 Trial

We Think Citius Pharmaceuticals (NASDAQ:CTXR) Can Afford To Drive Business Growth

Citius Pharmaceuticals, Inc. Reports Strong Clinical Community Engagement During Mino-Lok Phase 3 Trial-Related Webinar

Citius Pharmaceuticals shares rise in anticipation of Mino-Lok phase 3 results